Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Experimental drugs have extremely limited human consumption data. There is not enough reliable information about this substance. This is most likely because the substance is is not very old. Information on these substances is limite and incomplete. Please be cautioned. Always practice harm reduction.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.



Also known as:

  • [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](4-morpholinyl)methanon[German][ACD/IUPAC Name]
  • [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](4-morpholinyl)methanone[ACD/IUPAC Name]
  • [(8β)-6-Méthyl-9,10-didéhydroergolin-8-yl](4-morpholinyl)méthanone[French][ACD/IUPAC Name]
  • Methanone, [(8β)-9,10-didehydro-6-methylergolin-8-yl]-4-morpholinyl-[ACD/Index Name]
  • 4-Lysergic acid morpholine
  • 4-Lysergoylmorpholine
  • D-Lysergic acid morpholide
  • Ergoline-8-β-carboxylic acid, 9,10-didehydro-6-methyl-, morpholide
  • Lysergic acid morpholide
  • Morpholine, 4-(((8-β)-9,10-didehydro-6-methylergolin-8-yl)carbonyl)- (9CI)
  • Morpholine, 4-lysergoyl- (6CI,7CI)

Psychedelic of the lysergamide class, less potent by weight and produces a rather mild, dreamy and even sedating trip compared to its bigger brother LSD.


It is a close structural homolog of LSD known mainly for its obscurity, low relative potency, and a few comments that have been made on the "dream-like" sedation it produces as well as potential nausea and other potentially uncomfortable physical effects. LSM-775 was first investigated in animal models in 1957, where it was observed to be "qualitatively similar to LSD" albeit with a significantly lower potency and "half the duration". It was later briefly described as one of the many analogs of LSD by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), in which he mentions conflicting reports, with one stating that "75 micrograms is an effective dose, comparable to a similar dose of LSD, and the other stating that "between 350 and 700 micrograms was needed" while producing "fewer signs of cardiovascular stimulation and peripheral toxicity.

" Since then, it has been observed that the latter observation is a more accurate description of LSM-775’s potency in humans, meaning it possesses about 1/10th the potency of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of LSM-775, and it has very little history of human usage. It has recently appeared on the market alongside research chemical psychedelic lysergamides such as AL-LAD, ETH-LAD and PARGY-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors (although it is considered to be one of the least popular and available in the series).

Despite its low observed potency relative to LSD, it is still highly advised to approach this unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if one chooses to use it.





LSM-775 is a structural analog of lysergic acid, with a morpholinyl functional group bound to RN of the chemical structure.

This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).

SMILESCN1C[[email protected]@H](C=C2[[email protected]]1Cc3c[nH]c4c3c2ccc4)C(=O)N5CCOCC5
Std. InChiInChI=1S/C20H23N3O2/c1-22-12-14(20(24)23-5-7-25-8-6-23)9-16-15-3-2-4-17-19(15)13(11-21-17)10-18(16)22/h2-4,9,11,14,18,21H,5-8,10,12H2,1H3/t14-,18-/m1/s1
Avg. Mass337.4155 Da
Molecular Weight337.4155
Monoisotopic Mass337.179016 Da
Nominal Mass337
ChemSpider ID172695

Subscribe for the latest updates

Dosing Guide



LSM-775 Duration Data
Onset25-45 minutes
Duration8-13 hours
After-effects1-16 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Come up
After Effects
Test Kits
Marguis Test Result
Note 2:
Note 3:


Pharmacological Effects

LSM-775 likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSM-775’s efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

Subjective Effects

Physical Effects

Psychological Effects

The cognitive effects of LSM-775 can be broken down into several components which progressively intensify proportional to dosage. In comparison to other psychedelics such as psilocybin, AL-LAD and mescaline, LSM-775 is likely able to be described as generally more stimulating and fast-paced in terms of the specific style of thought stream(s) produced and contains a large number of potential effects. However, relative to other lysergamides, it has been noted as being more sedating and "dream-like", in a manner that has drawn comparisons to LSA. The most prominent of these cognitive effects generally include:

Visual Effects




The visual geometry that is potentially present throughout this trip can be likely described as more similar in appearance to that of MET or 2C-B than psilocin, or DMT. It can be tentatively be described through its variations as primarily intricate in complexity, algorithmic in form, structured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, immersive in-depth and consistent in intensity. At higher dosages, it may almost consistently result in states of Level 8A or Level 8B visual geometry.

Hallucinatory states

Auditory Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

It should be noted that these effects are the rarest and least reproducible those that can occur during a psychedelic experience. They are considered unique in that that simply taking more of the substance does not necessarily increase the chance they will occur, and are said to rely more on contextual factors such as the user's set and setting rather than the substance or dose itself. Their fullest manifestations are sometimes called "peak", "transcendent" or "transformative" experiences; however, they can still occur on a conceptual or cognitive level that can leave a lasting positive impact on the user.

Legal Status


  1. Gogerty, J. H.; Dille, J. M. (1975). "Pharmacology of d-lysergic acid morpholide (LSM)". Journal of Pharmacology and Experimental Therapeutics. 120 (3): 340–348.  1521-0103.  0022-3565. OCLC 1606914. PMID 13476356.
  2. Shulgin, Alexander; Shulgin, Ann (1997). "#26. LSD-25". TiHKAL: The Continuation. United States: Transform Press.  0-9630096-9-9. OCLC 38503252.
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
  4. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
  5. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
  6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.


Information made possible with:

  1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
  2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
  3. PubChem National Center for Bio Informatics
  4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
  5. Wikipedia

Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

Data is constantly updated so please check back later to see if there is any more available information on this substance.